首页> 美国卫生研究院文献>Filaria Journal >Treatment of co-infection with bancroftian filariasis and onchocerciasis: a safety and efficacy study of albendazole with ivermectin compared to treatment of single infection with bancroftian filariasis
【2h】

Treatment of co-infection with bancroftian filariasis and onchocerciasis: a safety and efficacy study of albendazole with ivermectin compared to treatment of single infection with bancroftian filariasis

机译:班克罗夫特丝虫病和盘尾丝虫病的合并感染的治疗:阿苯达唑和伊维菌素与单次感染班克罗夫特丝虫病的安全性和有效性研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundIn order to use a combination of ivermectin and albendazole for the elimination of lymphatic filariasis, it is important to assess the potential risk of increased adverse events in individuals infected with both lymphatic filariasis and onchocerciasis. We compared the safety and efficacy of albendazole (400 mg) in combination with ivermectin (150 micrograms/kg), for the treatment of co-infections of Wuchereria bancrofti and Onchocerca volvulus with single infection of W. bancrofti.
机译:背景技术为了使用伊维菌素和阿苯达唑的组合消除淋巴丝虫病,重要的是评估淋巴丝虫病和盘尾丝虫病感染者增加不良事件的潜在风险。我们比较了阿苯达唑(400毫克)与伊维菌素(150微克/千克)联合治疗Wuchereria bancrofti和Onchocerca volvulus合并感染并感染W. bancrofti的安全性和有效性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号